Payment overview · 2025
General Payments
$51.85
3 reported records · 2 companies
Healthcare provider profile · identity verified
Scott Bryan Tofil, MD
Allopathic & Osteopathic Physicians|Internal Medicine · YOUNGSTOWN, OH · NPI 1083618474
Verified facts
What the public records show
CMS Open Payments records show Scott Bryan Tofil, MD received $51.85 in general payments during 2025 across 3 reported records.
PFIZER INC. accounted for 66.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nurtec Odt.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.64 | 66.8% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.21 | 33.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $51.85 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.64 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 242 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
242 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 762 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 688 | 184 |
| Metoprolol Succinate | Metoprolol Succinate | 437 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 425 | 102 |
| Gabapentin | Gabapentin | 373 | 88 |
| Losartan Potassium | Losartan Potassium | 254 | 67 |
| Simvastatin | Simvastatin | 245 | 61 |
| Eliquis | Apixaban | 242 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 69 |
| Furosemide | Furosemide | 240 | 61 |
| Prednisone | Prednisone | 236 | 136 |
| Lisinopril | Lisinopril | 230 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 189 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 44 |
| Potassium Chloride | Potassium Chloride | 161 | 38 |
| Carvedilol | Carvedilol | 157 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 40 |
| Omeprazole | Omeprazole | 152 | 36 |
| Tramadol Hcl | Tramadol Hcl | 151 | 41 |
| Glimepiride | Glimepiride | 149 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 26 |
| Trulicity | Dulaglutide | 126 | 24 |
| Metformin Hcl | Metformin Hcl | 120 | 34 |
| Spironolactone | Spironolactone | 120 | 28 |
| Buspirone Hcl | Buspirone Hcl | 113 | 26 |
| Famotidine | Famotidine | 113 | 31 |
| Alprazolam | Alprazolam | 111 | 38 |
| Donepezil Hcl | Donepezil Hcl | 110 | 30 |
| Montelukast Sodium | Montelukast Sodium | 107 | 28 |
| Bupropion Xl | Bupropion Hcl | 106 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 26 |
| Allopurinol | Allopurinol | 96 | 20 |
| Januvia | Sitagliptin Phosphate | 95 | 21 |
| Topiramate | Topiramate | 94 | 20 |
| Mirtazapine | Mirtazapine | 90 | 23 |
| Ozempic | Semaglutide | 90 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 27 |
| Pregabalin | Pregabalin | 89 | 20 |
| Trazodone Hcl | Trazodone Hcl | 89 | 26 |
| Valsartan | Valsartan | 85 | 24 |
| Azithromycin | Azithromycin | 81 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 24 |
| Meloxicam | Meloxicam | 75 | 26 |
| Synthroid | Levothyroxine Sodium | 75 | 20 |
| Sertraline Hcl | Sertraline Hcl | 73 | 20 |
| Atenolol | Atenolol | 72 | 21 |
| Ezetimibe | Ezetimibe | 72 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 22 |
| Finasteride | Finasteride | 68 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 12 |
| Jardiance | Empagliflozin | 65 | 16 |
| Azelastine Hcl | Azelastine Hcl | 61 | 24 |
| Levetiracetam | Levetiracetam | 61 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 60 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 15 |
| Lorazepam | Lorazepam | 59 | 14 |
| Linzess | Linaclotide | 58 | 11 |
| Metformin Hcl Er | Metformin Hcl | 58 | 17 |
| Warfarin Sodium | Warfarin Sodium | 58 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 26 |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Sucralfate | Sucralfate | 53 | 18 |
| Lamotrigine | Lamotrigine | 48 | 11 |
| Clonidine Hcl | Clonidine Hcl | 46 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 12 |
| Bumetanide | Bumetanide | 45 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 17 |
| Alendronate Sodium | Alendronate Sodium | 43 | 13 |
| Clonazepam | Clonazepam | 42 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 42 | 11 |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 30 |
| Cefdinir | Cefdinir | 32 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 17 |
| Metolazone | Metolazone | 31 | 13 |
| Tradjenta | Linagliptin | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 26 |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | 11 |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Folic Acid | Folic Acid | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Caplyta | Lumateperone Tosylate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $51.85 · 3 records | PFIZER INC. | ACCRUFER, ELIQUIS, NURTEC ODT, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error